Public companies providing imaging devices and services continue to have a hard time making money for their shareholders, according to data from a recent industry survey by HealthCare Markets Group. Shares of imaging device manufacturers fell 4.6% in the
Public companies providing imaging devices and services continue to have a hard time making money for their shareholders, according to data from a recent industry survey by HealthCare Markets Group. Shares of imaging device manufacturers fell 4.6% in the first nine months of 1999 (end-September), compared to a 21% drop for the same period in 1998.
Among the biggest gainers were Vital Images, up 170%, and SonoSite, up 152%; the biggest losses were felt by Hologic, down 67%, and Fischer Imaging, down 56%.
Share price for imaging services vendors declined 5.8% during the first nine months of 1999, compared to a 32% decline for all of 1998. Overall, healthcare industry stock prices declined 2.8% in the first nine months of 1999, compared to a 1.9% increase in the same period of 1998.
Despite the poor performance, 1999 is still turning out to be a better year than 1998, which witnessed a 23% decline in share value for imaging device firms (SCAN 1/13/99). HMG of Hilton Head, SC, reviews the financial performance of publicly owned healthcare companies in 36 market segments.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.